This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Inovio Pharmaceuticals, Inc.
Drug Names(s): VGX-3400, SynCon pandemic avian influenza (H5N1) vaccine
Description: VGX-3400X is a proprietary, prophylactic DNA vaccine candidate designed to prevent infection with the avian influenza (H5N1). The plasmid vaccine is delivered into muscle tissue with the assistance of electroporation with the goal of achieving expression of the H5N1 influenza antigens.
VGX-3400X consists of three distinct DNA plasmids containing a universal consensus hemagglutinin (HA) antigen derived from different H5N1 flu viruses; a universal consensus neuraminidase (NA) antigen encompassing different N1 subtypes such as H5N1 and H1N1; and a universal consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E), both also encompassing N1-based viruses.
Additional information available to subscribers only: